Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinshukang is a Traditional Chinese Medicine (TCM) formulation developed by Tangshan Longshan Pharmaceutical Co., Ltd., primarily indicated for the treatment of coronary heart disease and angina pectoris. The medication is typically formulated as capsules or tablets and contains a combination of herbal extracts, including *Crataegus pinnatifida* (Hawthorn), *Salvia miltiorrhiza* (Danshen), and *Pueraria lobata* (Kudzu). Its therapeutic effects are attributed to its ability to promote blood circulation, remove blood stasis, and improve myocardial blood supply. Specifically, it works by dilating coronary vessels, reducing peripheral resistance, and inhibiting platelet aggregation, thereby relieving symptoms such as chest tightness and pain associated with Qi deficiency and blood stasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xinshukang.